Edwards Lifesciences Corp (NYSE:EW) Shares Sold by First National Bank of Omaha

First National Bank of Omaha decreased its position in Edwards Lifesciences Corp (NYSE:EW) by 21.5% in the 3rd quarter, Holdings Channel reports. The fund owned 26,747 shares of the medical research company’s stock after selling 7,344 shares during the period. First National Bank of Omaha’s holdings in Edwards Lifesciences were worth $5,882,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Nuveen Asset Management LLC grew its holdings in Edwards Lifesciences by 8,278.5% during the second quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock worth $730,013,000 after acquiring an additional 3,904,405 shares during the period. Bessemer Group Inc. lifted its position in Edwards Lifesciences by 56,300.0% during the second quarter. Bessemer Group Inc. now owns 503,652 shares of the medical research company’s stock valued at $93,045,000 after acquiring an additional 502,759 shares during the last quarter. Marshall Wace North America L.P. lifted its position in Edwards Lifesciences by 394.9% during the second quarter. Marshall Wace North America L.P. now owns 364,492 shares of the medical research company’s stock valued at $67,336,000 after acquiring an additional 290,838 shares during the last quarter. Jennison Associates LLC lifted its position in Edwards Lifesciences by 4.8% during the second quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock valued at $1,115,646,000 after acquiring an additional 275,182 shares during the last quarter. Finally, Thoroughbred Financial Services LLC lifted its position in Edwards Lifesciences by 20,429.8% during the second quarter. Thoroughbred Financial Services LLC now owns 267,503 shares of the medical research company’s stock valued at $26,750,000 after acquiring an additional 266,200 shares during the last quarter. 81.31% of the stock is owned by institutional investors.

A number of brokerages have weighed in on EW. Jefferies Financial Group lifted their price target on shares of Edwards Lifesciences from $210.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Piper Jaffray Companies lifted their price target on shares of Edwards Lifesciences from $240.00 to $255.00 and gave the company an “overweight” rating in a research report on Thursday, October 24th. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $217.00 to $250.00 and gave the company an “outperform” rating in a research report on Tuesday, October 22nd. Barclays lifted their price target on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research report on Wednesday, July 24th. Finally, BMO Capital Markets lifted their price target on shares of Edwards Lifesciences from $204.00 to $224.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $237.89.

In other news, Director William J. Phd Link sold 10,214 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $221.86, for a total transaction of $2,266,078.04. Following the transaction, the director now directly owns 16,817 shares in the company, valued at approximately $3,731,019.62. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 22,850 shares of the stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $216.70, for a total transaction of $4,951,595.00. Following the transaction, the chief executive officer now owns 95,770 shares in the company, valued at $20,753,359. The disclosure for this sale can be found here. Insiders sold 140,734 shares of company stock valued at $31,547,747 in the last 90 days. Company insiders own 1.63% of the company’s stock.

Shares of EW stock traded down $1.27 during trading on Friday, reaching $233.89. The company’s stock had a trading volume of 545,176 shares, compared to its average volume of 1,225,907. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.53 and a quick ratio of 2.74. The company has a market capitalization of $48.47 billion, a price-to-earnings ratio of 49.76, a P/E/G ratio of 2.81 and a beta of 0.82. The stock’s 50-day moving average price is $226.42 and its 200 day moving average price is $203.04. Edwards Lifesciences Corp has a 1-year low of $139.64 and a 1-year high of $241.82.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.19. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The business’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.07 earnings per share. On average, sell-side analysts anticipate that Edwards Lifesciences Corp will post 5.6 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: How much can an individual set aside as a catch-up contribution?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.